subject: Vision Shopsters: Benchmarking Drug Safety And Pharmacovigilance [print this page] Its clear to pharmaceutical and biotechnology executives that drug safety teams are vital to protecting patients and keeping drugs on the market. Some high-profile examples of poor drug safety efforts over the past decadeand even some more recently in 2010have prompted the pharma industry to invest more in drug safety. Beyond changes to investments and added resources, companies are beginning to regard drug safety in more strategic terms.
Benchmarking Drug Safety and Pharmacovigilance provides best practices for pharmaceutical and biotechnology teams to structure their drug safety teams, develop pharmacovigilance strategies, allocate budgets and headcounts appropriately, and learn when to initiate critical pharmacovigilance activities. Explore real-company strategies and metrics for companies drug safety and pharmacovigilance teams :
Learn what it means to develop a strategic drug safety team: Many drug company executives view drug safety as a required function or as nothing more than a cost center. This study uncovers best practices that top-notch drug safety and pharmacovigilance teams have in place to deliver strategic impact.
Optimize your drug safety team: Several factors affect the size and structure of drug safety and pharmacovigilance teams. This study shows how to align your team, assign responsibility for investigational and post- market products, determine the most appropriate activities to outsource, and understand how to choose among drug safety vendors.
Prove the drug safety teams value: Performance measurement for pharmacovigilance activities are few and far between. So how does a drug safety team demonstrate its impact to the bottom line? This study showcases best practices to measure and prove the value of a strategic drug safety team.
METRICS INTRODUCTION
Benchmarking Drug Safety and Pharmacovigilance' s three chapters include metrics detailing drug safety/pharmacovigilance budgets and outsourcing, structure and staffing, and timing of activities. In many cases throughout the report, data are broken down by company type - large, mid-size, small and biotechnology.
For more information on the report, kindly visit :
